In 2003-04, when the discussions were under way about drafting what is now CAMR, this issue did come up a few times in discussion. There was very little appetite to do that, it appeared, on the part of the federal government departments that were involved at the time, and I suspect that appetite is as little now as it was then, and perhaps for good reason. I think there is certainly a role for entities like CIDA to play, obviously in mobilizing funds and in drawing the attention of developing countries to the options that might be available to them to get lower-priced medicines, but this is fundamentally a mechanism that is about making the market conditions such that private actors—in this case generic drug companies—are going to see that it is worth their while because they will at least recoup their spending on this and make a small amount of profit, and about making it possible for developing countries to use this.
The idea is that the mechanism should be one that brings the purchaser and the producer together. I'm not sure you would necessarily improve the situation by sticking the government in the middle of that when you could actually just make that process work simply for the two parties instead of having the government as some sort of middleman.